サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1670830

医薬品連続製造の世界市場レポート 2025年

Pharmaceutical Continuous Manufacturing Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
医薬品連続製造の世界市場レポート 2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

医薬品連続製造の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.2％で41億5,000万米ドルに成長します。予測期間の成長は、ジェネリック医薬品製造の増加、バイオ医薬品製造、個別化医療製造、患者中心のアプローチへの注力に起因しています。予測期間における主な動向には、連続製造の採用、プロセス分析技術の統合、高度な自動化と協働ロボットの使用、戦略的提携とパートナーシップ、デジタル化と接続性などがあります。

様々な慢性疾患の有病率の増加が、今後の医薬品連続製造市場の成長を牽引すると予測されます。慢性疾患は一般に、1年以上続き、継続的な治療を必要とし、日常生活に支障をきたす状態と定義されます。継続的な製造プロセスにより、製薬企業は薬の生産を最適化し、効率化とコスト削減につなげることができます。このアプローチはまた、長期的な治療が必要な慢性疾患を管理するために特に重要な、必要不可欠な医薬品への幅広いアクセスを容易にします。例えば、2022年4月、慢性疾患プログラムに特化した米国の非営利団体National Association of Chronic Disease Directors（NACDD）の報告書によると、成人アメリカ人の60％近くが少なくとも1つの慢性疾患に罹患しており、約40％が複数の慢性疾患（MCC）に罹患しているといいます。このような状況は、2030年までに米国経済に年間2兆ドル、1人当たり8,600ドルの損失をもたらすと予測されています。その結果、慢性疾患の有病率の増加が医薬品連続製造市場を牽引すると予想されます。

産業オートメーションの台頭は、今後の医薬品連続製造市場の成長を牽引すると予想されます。産業オートメーションでは、コンピュータやロボットなどの制御システムを使用して、産業内のさまざまなプロセスや機械を管理し、人間の介入を代替または補完します。このオートメーションは、連続的な製造工程におけるモニタリングやリアルタイムのフィードバック制御を提供することで、医薬品連続製造を促進し、人的ミスの削減や一貫した製品品質の維持を支援します。例えば、2023年9月、ドイツを拠点とする専門的な非営利団体である国際ロボット連盟が発表した世界ロボット報告書によると、世界の工場における産業用ロボットの設置台数は55万3,052台であり、2022年には前年比5%の成長率を示すことが明らかになった。このように、産業オートメーションの増加が医薬品連続製造市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界医薬品連続製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の医薬品連続製造市場：成長率分析
  • 世界の医薬品連続製造市場の実績：規模と成長, 2019-2024
  • 世界の医薬品連続製造市場の予測：規模と成長, 2024-2029, 2034F
  • 世界医薬品連続製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の医薬品連続製造市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 統合継続システム
  • 制御とソフトウェア
  • 半連続システム
  • 世界の医薬品連続製造市場治療薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 巨大分子
  • 小分子
  • 世界の医薬品連続製造市場処方別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 固体形成
  • 液体および半固体の形成
  • 世界の医薬品連続製造市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 最終医薬品製造
  • 医薬品有効成分（API）製造
  • 世界の医薬品連続製造市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 製薬会社
  • 契約製造組織
  • その他のエンドユーザー
  • 世界の医薬品連続製造市場、統合連続システムのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 連続ミキサーシステム
  • 連続造粒システム
  • 連続打錠システム
  • 連続コーティングシステム
  • 世界の医薬品連続製造市場、制御とソフトウェアのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • プロセス分析技術（PAT）ツール
  • 製造実行システム（MES）
  • 自動化のための制御ソフトウェア
  • データ管理および視覚化ソフトウェア
  • 世界の医薬品連続製造市場、半連続システムのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • バッチから連続への移行システム
  • ハイブリッドシステム
  • 半連続造粒・乾燥システム

第7章 地域別・国別分析

  • 世界の医薬品連続製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の医薬品連続製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 医薬品連続製造市場：競合情勢
  • 医薬品連続製造市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Robert Bosch GmbH Overview, Products and Services, Strategy and Financial Analysis
    • Siemens AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • Corning Inc.
  • Vertex Pharmaceuticals
  • Lonza Group Ltd.
  • GEA Group AG
  • Catalent Inc.
  • Mettler Toledo
  • Patheon
  • Cytiva
  • Samsung Biologics Co.Ltd.
  • WuXi Biologics
  • Syntegon Technology GmbH
  • Coperion GmbH
  • Hosokawa Micron Group

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 医薬品連続製造市場2029：新たな機会を提供する国
  • 医薬品連続製造市場2029：新たな機会を提供するセグメント
  • 医薬品連続製造市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r25200

Pharmaceutical continuous manufacturing (PCM) is a streamlined process that involves the production of pharmaceutical goods from initiation to completion on a single, uninterrupted production line. This innovative approach is particularly utilized for manufacturing active pharmaceutical components through continuous flow chemical transformations and multistep syntheses, allowing for extended operational durations and potentially mitigating medicine shortages.

The primary categories of pharmaceutical continuous manufacturing products include integrated continuous systems, controls and software, and semi-continuous systems. The Integrated Continuous System (ICS) represents a comprehensive method for producing pharmaceutical items seamlessly on a continuous production line. These systems find application in the manufacturing of both large molecule and small molecule therapeutics, playing a vital role in producing solid formulations, liquids, and semi-solid formulations. ICS is deployed in various applications, including final drug product manufacturing and active pharmaceutical ingredient (API) manufacturing. This technology is adopted by diverse end-users such as pharmaceutical companies, contract manufacturing organizations, and other relevant entities in the pharmaceutical industry.

The pharmaceutical continuous manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical continuous manufacturing market statistics, including pharmaceutical continuous manufacturing industry global market size, regional shares, competitors with a pharmaceutical continuous manufacturing market share, detailed pharmaceutical continuous manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical continuous manufacturing industry. This pharmaceutical continuous manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical continuous manufacturing market size has grown rapidly in recent years. It will grow from $2.47 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to quality and efficiency improvements, reduced time-to-market, cost reduction and operational efficiency, regulatory support and guidelines, flexibility and scalability

The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $4.15 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to increasing generic drug production, biopharmaceutical manufacturing, personalized medicine manufacturing, focus on patient-centric approaches. Major trends in the forecast period include adoption of continuous manufacturing, integration of process analytical technology, use of advanced automation and robotics, strategic collaborations and partnerships, digitalization and connectivity.

The increasing prevalence of various chronic ailments is projected to drive the growth of the pharmaceutical continuous manufacturing market in the future. Chronic ailments are generally defined as conditions that last for a year or more, require ongoing medical treatment, and disrupt daily activities. Continuous manufacturing processes allow pharmaceutical companies to optimize medication production, leading to greater efficiency and reduced costs. This approach also facilitates wider access to essential medications, which is particularly critical for managing chronic conditions that necessitate long-term treatment. For example, in April 2022, a report from the National Association of Chronic Disease Directors (NACDD), a US-based non-profit organization focused on chronic disease programs, indicated that nearly 60% of adult Americans have at least one chronic disease, and about 40% have multiple chronic conditions (MCC). This situation is anticipated to cost the US economy $2 trillion annually, or $8,600 per person by 2030. Consequently, the growing prevalence of chronic ailments is expected to drive the pharmaceutical continuous manufacturing market.

The rise in industrial automation is anticipated to drive the growth of the pharmaceutical continuous manufacturing market in the future. Industrial automation involves using control systems, such as computers or robots, to manage various processes and machinery within an industry, replacing or supplementing human intervention. This automation facilitates pharmaceutical continuous manufacturing by providing monitoring and real-time feedback control in continuous manufacturing processes, helping to reduce human error and maintain consistent product quality. For instance, in September 2023, the World Robotics report published by the International Federation of Robotics, a Germany-based professional non-profit organization, revealed that there were 553,052 industrial robot installations in factories globally, representing a 5% year-on-year growth rate in 2022. Thus, the increase in industrial automation is propelling the growth of the pharmaceutical continuous manufacturing market.

Technological innovations are emerging as a prominent trend in the pharmaceutical continuous manufacturing market, with major companies actively developing new products to maintain their market positions. One notable example is the introduction of the USP Advanced Manufacturing Technology Lab by The United States Pharmacopeia (USP) in December 2022. This initiative includes the launch of R&D analytical solutions aimed at assisting drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM). The goal is to enhance geographic diversity in pharmaceutical manufacturing, thereby bolstering the resilience of the medicine supply chain. The lab services provided by USP facilitate the characterization of materials and the development and qualification of methods to ensure the quality of PCM-based medications.

Major companies in the pharmaceutical continuous manufacturing market are focusing on the development of advanced equipment, such as continuous manufacturing lines, to gain a competitive edge. For instance, WuXi STA, a China-based contract research development, and manufacturing organization (CRDMO), launched a Continuous Manufacturing (CM) line for oral solids in January 2023. This CM line, compliant with global cGMP regulations, introduces advancements in oral drug development by incorporating continuous direct compression equipment for various processes, including dispensing, blending, lubrication, tablet compression, and coating. Process Analytical Technology (PAT) is integrated into the system to monitor blending uniformity in real-time, ensuring high product quality.

In January 2023, Cambrex Corporation, a US-based contract development manufacturing organization (CDMO) for pharmaceuticals, acquired Snapdragon Chemistry Inc. This acquisition strengthened Cambrex's expertise in active pharmaceutical ingredient (API) process development in continuous flow manufacturing. Snapdragon Chemistry Inc., a US-based company specializing in API batch and continuous flow process development, was integrated to complement Cambrex's recent investments in endless flow process development capabilities. These initiatives collectively showcase the industry's commitment to leveraging technological innovations for advancements in pharmaceutical continuous manufacturing.

Major companies operating in the pharmaceutical continuous manufacturing market include Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRUDER LODIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV

Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmaceutical continuous manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical continuous manufacturing market consists of revenues earned by entities by providing manufacturing services such as mixing, granulation, coating, and tablet compression. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical continuous manufacturing market also includes sales of organic PCM and inorganic PCM techniques. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmaceutical Continuous Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmaceutical continuous manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmaceutical continuous manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmaceutical continuous manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Integrated Continuous System; Control And Software; Semi-Continuous System
  • 2) By Therapeutics Type: Large Molecule; Small Molecule
  • 3) By Formulation: Solid Formation; Liquid And Semi-Solid Formation
  • 4) By Application: Final Drug Product Manufacturing; Active Pharmaceutical Ingredient (API) Manufacturing
  • 5) By End-Users: Pharmaceutical Companies; Contract Manufacturing Organization; Other End-Users
  • Subsegments:
  • 1) By Integrated Continuous System: Continuous Mixer Systems; Continuous Granulation Systems; Continuous Tablet Press Systems; Continuous Coating Systems
  • 2) By Control and Software: Process Analytical Technology (PAT) Tools; Manufacturing Execution Systems (MES); Control Software for Automation; Data Management and Visualization Software
  • 3) By Semi-Continuous System: Batch-to-Continuous Transition Systems; Hybrid Systems; Semi-Continuous Granulation and Drying Systems
  • Companies Mentioned: Pfizer Inc.; Robert Bosch GmbH; Siemens AG; Novartis AG; Thermo Fisher Scientific Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmaceutical Continuous Manufacturing Market Characteristics

3. Pharmaceutical Continuous Manufacturing Market Trends And Strategies

4. Pharmaceutical Continuous Manufacturing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pharmaceutical Continuous Manufacturing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Pharmaceutical Continuous Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Pharmaceutical Continuous Manufacturing Market Growth Rate Analysis
  • 5.4. Global Pharmaceutical Continuous Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Pharmaceutical Continuous Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Pharmaceutical Continuous Manufacturing Total Addressable Market (TAM)

6. Pharmaceutical Continuous Manufacturing Market Segmentation

  • 6.1. Global Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Integrated Continuous System
  • Control And Software
  • Semi-Continuous System
  • 6.2. Global Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Large Molecule
  • Small Molecule
  • 6.3. Global Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Solid Formation
  • Liquid And Semi-Solid Formation
  • 6.4. Global Pharmaceutical Continuous Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Final Drug Product Manufacturing
  • Active Pharmaceutical Ingredient (API) Manufacturing
  • 6.5. Global Pharmaceutical Continuous Manufacturing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmaceutical Companies
  • Contract Manufacturing Organization
  • Other End-Users
  • 6.6. Global Pharmaceutical Continuous Manufacturing Market, Sub-Segmentation Of Integrated Continuous System, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Continuous Mixer Systems
  • Continuous Granulation Systems
  • Continuous Tablet Press Systems
  • Continuous Coating Systems
  • 6.7. Global Pharmaceutical Continuous Manufacturing Market, Sub-Segmentation Of Control and Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Process Analytical Technology (PAT) Tools
  • Manufacturing Execution Systems (MES)
  • Control Software for Automation
  • Data Management and Visualization Software
  • 6.8. Global Pharmaceutical Continuous Manufacturing Market, Sub-Segmentation Of Semi-Continuous System, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Batch-to-Continuous Transition Systems
  • Hybrid Systems
  • Semi-Continuous Granulation and Drying Systems

7. Pharmaceutical Continuous Manufacturing Market Regional And Country Analysis

  • 7.1. Global Pharmaceutical Continuous Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Pharmaceutical Continuous Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharmaceutical Continuous Manufacturing Market

  • 8.1. Asia-Pacific Pharmaceutical Continuous Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharmaceutical Continuous Manufacturing Market

  • 9.1. China Pharmaceutical Continuous Manufacturing Market Overview
  • 9.2. China Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharmaceutical Continuous Manufacturing Market

  • 10.1. India Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharmaceutical Continuous Manufacturing Market

  • 11.1. Japan Pharmaceutical Continuous Manufacturing Market Overview
  • 11.2. Japan Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharmaceutical Continuous Manufacturing Market

  • 12.1. Australia Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharmaceutical Continuous Manufacturing Market

  • 13.1. Indonesia Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharmaceutical Continuous Manufacturing Market

  • 14.1. South Korea Pharmaceutical Continuous Manufacturing Market Overview
  • 14.2. South Korea Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharmaceutical Continuous Manufacturing Market

  • 15.1. Western Europe Pharmaceutical Continuous Manufacturing Market Overview
  • 15.2. Western Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharmaceutical Continuous Manufacturing Market

  • 16.1. UK Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharmaceutical Continuous Manufacturing Market

  • 17.1. Germany Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharmaceutical Continuous Manufacturing Market

  • 18.1. France Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharmaceutical Continuous Manufacturing Market

  • 19.1. Italy Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharmaceutical Continuous Manufacturing Market

  • 20.1. Spain Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharmaceutical Continuous Manufacturing Market

  • 21.1. Eastern Europe Pharmaceutical Continuous Manufacturing Market Overview
  • 21.2. Eastern Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharmaceutical Continuous Manufacturing Market

  • 22.1. Russia Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharmaceutical Continuous Manufacturing Market

  • 23.1. North America Pharmaceutical Continuous Manufacturing Market Overview
  • 23.2. North America Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharmaceutical Continuous Manufacturing Market

  • 24.1. USA Pharmaceutical Continuous Manufacturing Market Overview
  • 24.2. USA Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharmaceutical Continuous Manufacturing Market

  • 25.1. Canada Pharmaceutical Continuous Manufacturing Market Overview
  • 25.2. Canada Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharmaceutical Continuous Manufacturing Market

  • 26.1. South America Pharmaceutical Continuous Manufacturing Market Overview
  • 26.2. South America Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharmaceutical Continuous Manufacturing Market

  • 27.1. Brazil Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharmaceutical Continuous Manufacturing Market

  • 28.1. Middle East Pharmaceutical Continuous Manufacturing Market Overview
  • 28.2. Middle East Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharmaceutical Continuous Manufacturing Market

  • 29.1. Africa Pharmaceutical Continuous Manufacturing Market Overview
  • 29.2. Africa Pharmaceutical Continuous Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Pharmaceutical Continuous Manufacturing Market, Segmentation By Therapeutics Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Pharmaceutical Continuous Manufacturing Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharmaceutical Continuous Manufacturing Market Competitive Landscape And Company Profiles

  • 30.1. Pharmaceutical Continuous Manufacturing Market Competitive Landscape
  • 30.2. Pharmaceutical Continuous Manufacturing Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Robert Bosch GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Pharmaceutical Continuous Manufacturing Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline Plc.
  • 31.2. Eli Lilly and Company
  • 31.3. Corning Inc.
  • 31.4. Vertex Pharmaceuticals
  • 31.5. Lonza Group Ltd.
  • 31.6. GEA Group AG
  • 31.7. Catalent Inc.
  • 31.8. Mettler Toledo
  • 31.9. Patheon
  • 31.10. Cytiva
  • 31.11. Samsung Biologics Co.Ltd.
  • 31.12. WuXi Biologics
  • 31.13. Syntegon Technology GmbH
  • 31.14. Coperion GmbH
  • 31.15. Hosokawa Micron Group

32. Global Pharmaceutical Continuous Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmaceutical Continuous Manufacturing Market

34. Recent Developments In The Pharmaceutical Continuous Manufacturing Market

35. Pharmaceutical Continuous Manufacturing Market High Potential Countries, Segments and Strategies

  • 35.1 Pharmaceutical Continuous Manufacturing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Pharmaceutical Continuous Manufacturing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Pharmaceutical Continuous Manufacturing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer